BioTech Weekly - Jun 16-22, 2025 (Week 25)
- Author
- Ernst
- Published
- Tue 24 Jun 2025
- Episode Link
- None
🚨 BioTech Breakthroughs You Can't Miss – This Week in 7:30min Minutes 🎧
This week’s roundup features 14 key articles across 5 major categories (Strategic & Leadership Updates, Financing & Transactions, Clinical & Regulatory Developments, Policy & Market Shifts, Industry Vision & Commentary). From FDA policy moves and major layoffs to new funding rounds and pediatric trials, this summary highlights the momentum and challenges shaping biotech today.
🔬 Whether you're an investor, scientist, or biotech enthusiast, this episode is your shortcut to staying informed.
#biotech #pharmaceuticals #healthcareinnovation #podcast #drugdevelopment #clinicaltrials #biotechnews #lifesciences #investors #healthtech
Sources
🔍 Strategic Moves & Leadership Updates
- 👉 BMS banks on Wall Street vet for long-term strategy guidance— Chutes & Ladders
- 👉 FDA's CBER head dons extra hats with new CMO, CSO titles
- 👉 Isomorphic Labs taps CMO, plants roots in Boston
💰 Financing & Transactions
- 👉 PharmAla Files Preliminary Base Shelf Prospectus
- 👉 Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib
- 👉 PSYENCE GROUP INC. Announces Offering of up to C$600,000
🧪 Clinical & Regulatory News
- 👉 LabPMM® Receives New York State Approval for the NPM1 MRD Assay
- 👉 enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- 👉 Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone
⚖️ Policy & Market Shifts
- 👉 FDA blocks new clinical trials that ship cells from US to China
- 👉 Industry reacts as FDA reportedly puts cell and gene therapy chief on leave
- 👉 Prothena lays off 63% of employees after phase 3 trial fail
- 👉 Syncona shifts biotech investment strategy amid tough market
🌍 Long-Term Vision
